Souhaitez-vous accéder aux communiqués récents ?

JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program

Inozyme Pharma CEO Doug Treco will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme's COO Matt Winton will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with...